Related Experiment Video

Updated: May 13, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

Bojko Bjelakovic1, Mila Bojanovic, Stevo Lukic

  • 1Clinic of Pediatrics, Clinical Center, Nis, Serbia. bojko968@gmail.com

Drug Design, Development and Therapy
|March 8, 2013
PubMed

Insights

Propranolol, a beta-blocker, effectively treated recurrent nosebleeds in seven children when other methods failed. This medication shows promise as a second-line therapy for pediatric epistaxis.

Area of Science:

  • Pediatric Medicine
  • Cardiology
  • Pharmacology

Background:

  • Recurrent primary epistaxis in children often proves resistant to conventional treatments.
  • Beta-blockers possess properties like negative inotropy, peripheral vasoconstriction, and antiangiogenesis.
  • These characteristics suggest potential therapeutic applications in managing epistaxis.

Purpose of the Study:

  • To evaluate the effectiveness of propranolol as a treatment for recurrent primary epistaxis in children.
  • To explore the potential of beta-blocker characteristics in managing pediatric nosebleeds.

Main Methods:

  • A case series involving seven children with recurrent primary epistaxis unresponsive to standard care.
  • Propranolol administered at a dosage of 1.5-2 mg/kg/day, divided into three doses, as a second-line therapy.
  • Observation period from June 2010 to March 2012.

Main Results:

  • Propranolol demonstrated overall effectiveness in all seven pediatric patients.
  • The medication successfully terminated epistaxis in the observed cases.
  • No adverse events were reported in the provided abstract.

Conclusions:

  • Propranolol appears to be a favorable and effective treatment option for children experiencing recurrent primary epistaxis.
  • Further research is warranted to confirm these findings in a larger cohort.
  • The unique properties of beta-blockers may offer a novel approach to epistaxis management.

Keywords:
beta-blockerchildrenepistaxis

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Epistaxis01:30

Epistaxis

Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...